Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Academic Article uri icon

Overview

authors

  • Roboz, Gail J
  • Döhner, Hartmut
  • Pocock, Christopher
  • Dombret, Herve
  • Ravandi, Farhad
  • Jang, Jun Ho
  • Selleslag, Dominik
  • Mayer, Jiři
  • Martens, Uwe M
  • Liesveld, Jane
  • Bernal, Teresa
  • Wang, Ming Chung
  • Yu, Peiwen
  • Shi, Ling
  • Guo, Shien
  • La Torre, Ignazia
  • Skikne, Barry
  • Dong, Qian
  • Braverman, Julia
  • Nehme, Salem Abi
  • Beach, C L
  • Wei, Andrew H

publication date

  • December 1, 2021

Research

keywords

  • Leukemia, Myeloid, Acute
  • Quality of Life

Identity

PubMed Central ID

  • PMC8634169

Scopus Document Identifier

  • 85120738327

Digital Object Identifier (DOI)

  • 10.3324/haematol.2021.279174

PubMed ID

  • 34551506

Additional Document Info

volume

  • 106

issue

  • 12